Skip to content

IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

This presentation reports the results from IPSOS (NCT03191786), a global, open-label, randomized, phase III study of atezolizumab versus single-agent chemotherapy in patients ineligible for first-line platinum-doublet chemotherapy. The presented data include the primary endpoint of overall survival, secondary endpoints such as OS rates, ORR, PFS, and DOR, and an assessment of safety and quality of life measures.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically